"The Program will help Government of Odisha scale up existing...
Category:
Disaster & Management
Latest
IPCC report a call to action for all, especially countries like India: Co-authors
As per the report's indicators, India, with a large coastline and...
Global insured losses from natural catastrophes break through USD 100 billion threshold again in 2022: Swiss Re
This reaffirms the trend of a 5–7% average annual increase in...
Trump says evidence ties Covid-19 to Wuhan lab
Washington: As the US recorded more than 2,000 deaths on three consecutive days, President Donald Trump launched a scathing attack on China on Thursday. He said that the World Health Organization should be ashamed of itself, and likened it to a public relations...
Covid-19 Pandemic:US life insurance claims may touch $7.2 bn
The estimate includes costs for policyholders between the ages of 56 and 74, which are projected to reach as much as a combined $4.1 billion for individual and group plans, the researcher said in a study released Thursday. Life insurers are in good shape and should be able to manage surging costs, according to the report’s author, Samantha Chow.
Individual policies would account for 81% of claims, while group plans such as those offered by employers would make up the rest, the Aite study found. Insurers’ main challenge will be how to handle claims as economic hardship spreads, Chow said.
“The biggest issue is going to be that these beneficiaries that are calling after losing a loved one who might have passed as a result of Covid-19 — they’ve incurred a lot of health-care costs,” she said. “They might need the money really quickly in order to survive.”
UK watchdog goes to court to clarify coronavirus business insurance
“This will assist both insurers and the insured. It will not determine how much is payable under individual policies, but will provide the basis for doing so,” the FCA said in a statement on Friday.
India extends nationwide lockdown,to allow relaxations in lower-risk zones
The biggest and most economically-important cities, including New Delhi, Mumbai, Bengaluru, Chennai and Ahmedabad, would all be classed as red zones, infection hotspots, and kept under strict lockdown.
Maker of coronavirus trial drug aims for wide distribution – Gilead CEO
Gilead Sciences, which manufactures remdesivir, is focused on making the experimental coronavirus drug accessible and affordable to as many people as possible once it is approved, Chief Executive Officer Daniel O’Day said on Friday. Interest in...
U.S. emergency approval broadens use of Gilead’s COVID-19 drug remdesivir
A draft study abstract released inadvertently by the World Health Organization (WHO) last week said remdesivir failed to improve patients’ condition or reduce the pathogen’s presence in the bloodstream. The drugmaker said the findings were inconclusive because the study was terminated early.
Fauci says leak concerns fueled his White House revelation of Gilead drug results
The dramatic announcement by Dr Anthony Fauci in the Oval Office on Wednesday prompted concerns among scientists that the Trump administration was raising hopes about a coronavirus treatment before sharing the full data with researchers.
Bodies found in unrefrigerated trucks in New York during COVID-19 pandemic
NEW YORK : The city of New York delivered a freezer truck to a funeral home on Wednesday after it was found to be storing dead bodies in unrefrigerated U-Haul vehicles, a Reuters eyewitness said. The eyewitness saw bodies in a U-Haul van and said two...
half of world’s workforce risks losing livelihoods in pandemic: ILO
“It shows I think in the starkest possible terms that the jobs employment crisis and all of its consequences is deepening by comparison with our estimates of 3 weeks ago,” ILO Director-General Guy Ryder told a briefing, foreseeing a “massive” poverty impact.Already, wages of the world’s 2 billion informal workers plunged by an estimated global average of 60% in the first month that the crisis unfolded in each region, the ILO said.
India’s Glenmark to conduct trials for potential COVID-19 drug
Favipiravir, manufactured under the brand name Avigan by a unit of Japan’s Fujifilm Holdings Corp (4901.T) and approved for use as an anti-flu drug in the Asian island country in 2014, has been effective, with no obvious side-effects, in helping coronavirus patients recover, a Chinese official told reporters at a news conference last month.
“After having successfully developed the API and the formulations … Glenmark is all geared to immediately begin clinical trials on favipiravir on COVID-19 patients in India,” Sushrut Kulkarni, executive vice-president for Global R&D, Glenmark Pharmaceuticals, said in a statement.